Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.44 - $112.17 $15 Million - $25 Million
-222,700 Reduced 59.99%
148,500 $15.2 Million
Q2 2024

Aug 15, 2024

SELL
$62.76 - $81.61 $11.7 Million - $15.2 Million
-186,600 Reduced 33.45%
371,200 $28.2 Million
Q1 2024

May 07, 2024

BUY
$72.35 - $88.99 $20.5 Million - $25.3 Million
283,800 Added 103.58%
557,800 $41.9 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $9.71 Million - $18.4 Million
229,000 Added 508.89%
274,000 $20.2 Million
Q3 2023

Nov 14, 2023

BUY
$39.12 - $49.85 $1.76 Million - $2.24 Million
45,000 New
45,000 $2.07 Million
Q1 2023

May 16, 2023

BUY
$25.42 - $33.52 $1.84 Million - $2.43 Million
72,400 Added 48.59%
221,400 $5.78 Million
Q4 2022

Feb 14, 2023

BUY
$18.46 - $36.37 $2.75 Million - $5.42 Million
149,000 New
149,000 $4.44 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.62B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.